815 related articles for article (PubMed ID: 23264400)
21. MicroRNA-146b-3p Promotes Cell Metastasis by Directly Targeting
Yu C; Zhang L; Luo D; Yan F; Liu J; Shao S; Zhao L; Jin T; Zhao J; Gao L
Thyroid; 2018 Dec; 28(12):1627-1641. PubMed ID: 30244634
[No Abstract] [Full Text] [Related]
22. Long noncoding RNA PVT1 enhances the viability and invasion of papillary thyroid carcinoma cells by functioning as ceRNA of microRNA-30a through mediating expression of insulin like growth factor 1 receptor.
Feng K; Liu Y; Xu LJ; Zhao LF; Jia CW; Xu MY
Biomed Pharmacother; 2018 Aug; 104():686-698. PubMed ID: 29803929
[TBL] [Abstract][Full Text] [Related]
23. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
Paulson L; Shindo M; Schuff K; Corless C
Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
[TBL] [Abstract][Full Text] [Related]
24. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of MiR-431 expression associated with lymph node metastasis and promotes cell invasion in papillary thyroid carcinoma.
Liu Y; Li L; Liu Z; Yuan Q; Lu X
Cancer Biomark; 2018; 22(4):727-732. PubMed ID: 29945344
[TBL] [Abstract][Full Text] [Related]
26. MiR-146b-5p Regulates the Expression of Long Noncoding RNA
Peng Y; Fang X; Yao H; Zhang Y; Shi J
Cancer Biother Radiopharm; 2021 Jun; 36(5):433-440. PubMed ID: 32343601
[No Abstract] [Full Text] [Related]
27. MicroRNA-146b-5p as an oncomiR promotes papillary thyroid carcinoma development by targeting CCDC6.
Jia M; Shi Y; Li Z; Lu X; Wang J
Cancer Lett; 2019 Feb; 443():145-156. PubMed ID: 30503553
[TBL] [Abstract][Full Text] [Related]
28. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
[TBL] [Abstract][Full Text] [Related]
29. MicroRNAs miR-146-5p and let-7f as prognostic tools for aggressive papillary thyroid carcinoma: a case report.
Geraldo MV; Fuziwara CS; Friguglieti CU; Costa RB; Kulcsar MA; Yamashita AS; Kimura ET
Arq Bras Endocrinol Metabol; 2012 Nov; 56(8):552-7. PubMed ID: 23295297
[TBL] [Abstract][Full Text] [Related]
30. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma.
Wang Z; Zhang H; Zhang P; Dong W; He L
Tumour Biol; 2016 Jun; 37(6):7633-44. PubMed ID: 26687649
[TBL] [Abstract][Full Text] [Related]
32. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
Xing M
Endocr Rev; 2007 Dec; 28(7):742-62. PubMed ID: 17940185
[TBL] [Abstract][Full Text] [Related]
33. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Xing M; Westra WH; Tufano RP; Cohen Y; Rosenbaum E; Rhoden KJ; Carson KA; Vasko V; Larin A; Tallini G; Tolaney S; Holt EH; Hui P; Umbricht CB; Basaria S; Ewertz M; Tufaro AP; Califano JA; Ringel MD; Zeiger MA; Sidransky D; Ladenson PW
J Clin Endocrinol Metab; 2005 Dec; 90(12):6373-9. PubMed ID: 16174717
[TBL] [Abstract][Full Text] [Related]
34. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
Jo YS; Li S; Song JH; Kwon KH; Lee JC; Rha SY; Lee HJ; Sul JY; Kweon GR; Ro HK; Kim JM; Shong M
J Clin Endocrinol Metab; 2006 Sep; 91(9):3667-70. PubMed ID: 16772349
[TBL] [Abstract][Full Text] [Related]
35. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features.
Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O
Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472
[TBL] [Abstract][Full Text] [Related]
36. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
[TBL] [Abstract][Full Text] [Related]
37. miR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor α.
Huang C; Cai Z; Huang M; Mao C; Zhang Q; Lin Y; Zhang X; Tang B; Chen Y; Wang X; Qian Z; Ye L; Peng Y; Xu H
J Clin Endocrinol Metab; 2015 Feb; 100(2):E204-13. PubMed ID: 25423566
[TBL] [Abstract][Full Text] [Related]
38. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
[TBL] [Abstract][Full Text] [Related]
39. MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.
Sondermann A; Andreghetto FM; Moulatlet AC; da Silva Victor E; de Castro MG; Nunes FD; Brandão LG; Severino P
Clin Exp Metastasis; 2015 Aug; 32(6):521-30. PubMed ID: 26007293
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
Geraldo MV; Nakaya HI; Kimura ET
Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
